DailyIQ
Last updated1 minute ago

TFX·Teleflex Incorporated

$123.79
-0.65 (-0.52%)
High
$124.89
Open
$123.86
Market Cap
5.27B
52W High
$145.00
Low
$123.11
P. Close
$123.79
P/E
-
52W Low
$90.63
Fwd P/E
11.37
DailyIQ Est.
$155.37
Inst. Ownership
58.0%
Short Interest
9.56%
Days to Cover
4.1
Div. Yield
1.09%
Next Ex-Div
~Nov 11
Technical Score (1D)
53
NEUTRAL
News Sentiment
62
BULLISH
TFX scores 53 on the 1D technical view with a NEUTRAL signal and mixed momentum. Price action is in a neutral range - the market is coiling, and neither side has been willing to push to a definitive break. Sentiment at 62 is diverging from the flat technical backdrop, removing sentiment as a directional catalyst for now. Consolidations like this are often a sign that the market is waiting for new information before committing capital in either direction. The range between $119.46 and $129.42 is well-defined. When this kind of compression resolves - particularly if it resolves with a gap or range-expansion bar - the follow-through tends to be more sustained than a typical breakout because of the energy that builds during the quiet phase. Coiled setups like this are as much about time as they are about price - the longer TFX compresses between $119.46 and $129.42 without a catalyst, the more the eventual move tends to compensate. Watching for a volume spike on the actual break, rather than trying to anticipate direction from the shape of the range, has historically been the more reliable approach.
LOW TARGET
$138 +11.5%
2 analysts
MEAN TARGET
$155 +25.0%
14 analysts
HIGH TARGET
$170 +37.3%
5 analysts
PRICE RANGE
$138.00 - $170.00
SB / B / H / S / SS
1/7/11/1/1
DAILYIQ EST.
$155.37 (+25.5%)
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NYQ
Country
United States
Symbol
TFX
Description
Teleflex Incorporated is a global medical device manufacturer specializing in single-use products designed for a broad range of diagnostic and therapeutic procedures. The company's core value proposition lies in its diverse portfolio, encompassing vascular access, interventional, anesthesia, surgical, urology, and respiratory products, catering to critical care and surgical applications. Teleflex's offerings, including the Arrow brand and the UroLift System, are utilized in hospitals, healthcare settings, and home care environments. Its competitive advantage is derived from a wide product range and a focus on providing solutions for a variety of medical needs. Established in 1943, Teleflex continues to serve healthcare providers worldwide from its headquarters in Wayne, Pennsylvania.
Bought (1Y)
0 shares
$0
Sold (1Y)
4,054 shares
$526K
Salmon Sean-
Award/Grant4,444 shares2026-09-08
Salmon Sean-
Award/Grant674 shares2026-09-08
Weidman Jason R.President and CEO
Award/Grant26,071 shares2026-06-08
Weidman Jason R.President and CEO
Award/Grant53,983 shares2026-06-08
RANDLE STUART A-
Award/Grant2,192 shares2026-06-08
38/ 100
Bearish
Overall: Bearish
✕Revenue declining year over year
✕Negative net margin
✓Positive operating cash flow
Gross Margin
56.2%
Net Margin
-45.4%
Revenue CAGR
0.2%
Current Ratio
2.54x
Debt / Equity
0.85x
Return on Equity
-29.0%
Earnings Summary
Teleflex Incorporated is a global medical device manufacturer focused on single‑use products for diagnostic and therapeutic procedures, spanning vascular access, interventional, anesthesia, surgical, urology, and respiratory markets. Operating within the medical instruments and supplies sector, the company leverages a broad portfolio, including the Arrow brand and UroLift System, to serve hospitals and home‑care settings worldwide. In the most recent quarters, Teleflex posted EPS of $3.89 in Q4 2024 and $2.91 in Q1 2025, both slightly above analyst expectations, while revenue grew to $795.4 million and $700.7 million respectively, reflecting a modest decline from the prior year but maintaining a positive trend. The company’s Q2 2025 EPS of $3.73 beat estimates and revenue of $780.9 million, whereas Q3 2025 EPS of $3.67 and revenue of $892.9 million continued the upward trajectory, indicating accelerating earnings momentum. Historically, Teleflex has shown a YoY revenue growth pattern with occasional EPS misses, such as the sharp drop to $1.93 in Q4 2025, yet it has consistently beat earnings estimates in the majority of recent quarters. Recent news highlights a peer‑reviewed study confirming a 70 % reduction in infection risk with Arrowg+ard technology, reinforcing Teleflex’s infection‑control leadership, and a Bank of America upgrade to Buy with a $158 target, citing product pipeline strength and governance refresh. Forward‑looking watch points include monitoring the impact of the board addition of Sean M. Salmon on capital allocation, the integration timeline of the OEM divestiture‑backed buyback program, and the company’s ability to sustain EPS growth amid the Q4 2025 revenue shortfall.

EPS

EstBeatMiss
$0.84$1.67$2.50$3.33$4.15Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.89 - -
Q2'26$1.29$1.76+36.0%
Q1'26$1.22$1.39+13.6%
Q4'25$3.77$1.93-48.8%
Q3'25$3.38$3.67+8.6%
Q2'25$3.37$3.73+10.8%

Revenue

EstBeatMiss
$480M$607M$734M$860M$987MQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$572M - -
Q2'26$565M$570M+0.9%
Q1'26$539M$548M+1.8%
Q4'25$928M$569M-38.7%
Q3'25 - $893M -
Q2'25 - $781M -

Market Data

TFX Stock Snapshot

NEUTRAL53/100
$123.79−$0.65 (0.5%)
Market cap
5.27B
Day range
$123.11 – $124.89
News sentiment
62/100 · Bullish
Analyst target
$154.73 (+25.0%)
Consensus
Hold · 21 analysts
52-week range+36.6% off low · -14.6% from high
$90.63$145.00
Price $123.79 DailyIQ Est. $155.37

Neither side has the upper hand on TFX right now, and its momentum ranks near the middle of DailyIQ's universe. At this size, a single catalyst moves the stock further than it would a larger peer.

Reverse DCF

What growth is priced into TFX?

RICH

At today's price, Teleflex Incorporated needs to grow free cash flow about 177.4% a year for the next 10 years to justify its valuation at a 6.98% cost of capital. Over its actual history it has compounded free cash flow at 0.9% a year, so the market is asking for 176.5 percentage points above its own delivered rate. On that basis TFX looks priced above what its own growth record supports.

Implied FCF growth
177.4%
Historical FCF CAGR
0.9%
Growth gap
+176.5 pts
Verdict
RICH
Discount rate (WACC)
6.98%
Beta
0.70

Behaviour On Record

What TFX's own history says about today's numbers

Realized volatility (21d)
22.5% 43rd pct
Below its peak
-72.0%
vs 200-day average
+0.3%
Up days (1y)
47%

Teleflex Incorporated is currently running 22.5% annualised volatility over the last 21 sessions. Measured against TFX's own 13 years of daily returns rather than a market-wide average, that is the 43rd percentile — close to its own typical level, against a typical reading of 24.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

TFX is trading -72.0% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -29.1%, and the deepest was -47.4% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +0.3% from its 200-day moving average. Against every other day in its history, that gap ranks at the 39th percentile — close to the gap it normally carries. Over the past year TFX closed higher on 47% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 13 years of records, TFX finished the month higher 6 of 13 times, with a median return of -3.2% and an average of -2.3%. Its strongest month historically has been November at +3.5% on average, its weakest September at -3.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: TFX has opened more than 2% away from the prior close in 93 of 3,267 sessions (2.8% of the time), with the largest gaps running +25.0% and -10.3%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, TFX moved an average of 2.1% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.0% and a largest of -2.8%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against TFX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of TFX's sector?

Teleflex Incorporated sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for TFX?

CallsPuts

For Teleflex Incorporated's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.14), with at-the-money implied volatility around 72.4%. The options market is pricing roughly a ±6.0% move by that expiry — a range of about $115.95–$130.77.

Put/call ratio (2026-10-16)
0.14
ATM implied volatility
72.4%
Total open interest
351
Expected move by 2026-10-16
±6.0% ($115.95–$130.77)

Analyst Rating Changes

Are analysts turning bullish or bearish on TFX?

B of A Securities most recently upgraded Teleflex Incorporated to Buy on Sep 28, 2026 with a price target of $158 (from $145). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
B of A Securities — Buy
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Sep 28, 2026B of A SecuritiesUpgradeNeutral → Buy$145 → $158
Aug 25, 2026NeedhamMaintainedBuy$159 → $170
Aug 11, 2026UBSMaintainedNeutral$145 → $158
Aug 10, 2026Truist SecuritiesMaintainedHold$143 → $150
Aug 7, 2026Piper SandlerReiteratedOverweight$160 → $169
Jul 31, 2026NeedhamMaintainedBuy$147 → $159
Jul 28, 2026UBSInitiatedNeutral$145
Jul 15, 2026MizuhoMaintainedNeutral$140 → $145
Jul 9, 2026BMO CapitalInitiatedOutperform$159
Jun 8, 2026Piper SandlerUpgradeNeutral → Overweight$140 → $160
May 11, 2026Truist SecuritiesReiteratedHold$135 → $143
May 8, 2026RBC CapitalUpgradeSector Perform → Outperform$135 → $155

Peers & ETF holders

TFX peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

62/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Teleflex Incorporated announced that patient enrollment in its BIOMAG™-LL clinical study for the Freesolve™ Resorbable Magnesium Scaffold had been completed. The study will assess safety and performance of 35 mm and 40 mm scaffold lengths in treating de novo coronary lesions up to 38 mm. Completion of enrollment is a milestone that supports the company’s strategy to expand evidence for its coronary device portfolio. The data will inform future regulatory submissions and potential market adoption. This development signals a positive step in Teleflex’s product development pipeline.
What did this article say?
Teleflex Incorporated completed enrollment of 102 patients across 14 European centers for the BIOMAG-LL clinical study, which evaluates 35 mm and 40 mm Freesolve® Resorbable Magnesium Scaffolds in treating long de novo coronary lesions up to 38 mm. The study aims to assess safety and clinical performance of these devices in long lesions, a challenging area for interventional cardiology. Completion of enrollment marks a significant milestone toward progressing the trial into subsequent phases and potentially accelerating regulatory submissions. The move underscores Teleflex’s commitment to expanding its cardiovascular portfolio and addressing unmet needs in complex lesion treatment.
What did this article say?
Teleflex (NYSE:TFX) released the full transcript of its second‑quarter 2026 earnings call on October 8. The transcript provided detailed commentary from management on financial performance, operational highlights, and future outlook. No new guidance or material corporate actions were disclosed during the call. The release offers investors a comprehensive view of the company’s quarterly narrative but does not alter the existing market perception of TFX.
What did this article say?
The article compares Teleflex (TFX) and SONOVA Holding (SONVY) for value investors, highlighting TFX’s higher Zacks Rank of #2 versus SONVY’s #3. It notes that TFX’s earnings estimate revisions have been more robust, suggesting a stronger analyst outlook. The piece also discusses how TFX scores favorably on traditional value metrics such as P/E, P/S, earnings yield, and cash flow, indicating potential undervaluation. Overall, the analysis positions TFX as the more attractive value play for investors seeking upside.
What did this article say?
Teleflex Incorporated released a peer‑reviewed study published in the American Journal of Infection Control that found its Arrowg+ard™‑protected central venous catheters reduced the hazard of central line‑associated bloodstream infections by 70% over 30 days. The multinational trial included 1,750 critically ill patients across six hospitals in four countries. The significant reduction in CLABSI risk translates into lower patient morbidity, shorter hospital stays, and reduced healthcare costs. The findings reinforce Teleflex’s position as a leader in infection‑control medical devices and support future market growth.
What did this article say?
Teleflex shares rose 4.3% on September 29 after BofA Securities upgraded the stock to Buy and raised its price target to $158 from $145. The rally followed the appointment of veteran medical‑technology executive Sean M. Salmon to the board, effective September 8, 2026. Analysts noted that the company’s consensus EPS estimate for the upcoming quarter had increased 4.3% over the past month, supporting the positive market reaction. Despite a 47.7% year‑over‑year decline in earnings per share and a 37% drop in revenue, the upgrade and board addition were viewed as catalysts for near‑term upside.
What did this article say?
BofA Securities upgraded Teleflex (TFX) from Neutral to Buy and raised its price target from $145 to $158, prompting a 4.5% jump in the stock during the afternoon session. The analyst upgrade attracted buying interest from investors following the recommendation. The move was seen as a meaningful catalyst but did not fundamentally alter the market’s long‑term view of the company.

Technical Analysis

Real-time indicators across multiple timeframes

53
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $2.88B combined position · 17 adding, 8 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy5,431,81812.82%$688.54M2026-08-07
Vanguard Group Inc▼ Sell4,759,01511.23%$580.79M2026-01-29
Janus Henderson Group plc▲ Buy4,291,31110.13%$513.28M2026-05-18
Millennium Management LLC▲ Buy1,442,1033.40%$182.80M2026-08-14
Citadel Advisors LLC▼ Sell1,140,9502.69%$144.63M2026-09-02
Geode Capital Management, LLC▲ Buy1,039,9772.45%$131.85M2026-08-12
Goldman Sachs Group Inc▲ Buy905,7792.14%$114.82M2026-08-14
Norges Bank▲ Buy684,4251.62%$86.76M2026-08-12
Morgan Stanley▲ Buy591,3011.40%$74.95M2026-08-13
Invesco Ltd.▲ Buy573,9141.35%$72.75M2026-08-14
Bank of America Corp▲ Buy482,4571.14%$61.16M2026-08-14
JPMorgan Chase & Co▲ Buy394,5020.93%$50.56M2026-08-12
Balyasny Asset Management L.P.▼ Sell315,2120.74%$39.96M2026-08-14
Northern Trust Corp▲ Buy306,6070.72%$38.87M2026-08-13
AQR Capital Management LLC▲ Buy280,6370.66%$35.21M2026-08-14
Verition Fund Management LLC▲ Buy98,0270.23%$12.43M2026-08-14
Gotham Asset Management, LLC▲ Buy95,4350.23%$12.10M2026-08-14
Renaissance Technologies LLC▲ Buy75,7000.18%$9.60M2026-08-13
Moore Capital Management, LP▼ Sell52,1750.12%$6.61M2026-08-14
Prudential Financial Inc▼ Sell40,0130.09%$5.07M2026-08-12
Brevan Howard Capital Management LP▲ Buy24,5970.06%$3.12M2026-08-14
Blackstone Inc.▲ New24,1410.06%$3.06M2026-08-14
AllianceBernstein L.P.▼ Sell20,4410.05%$2.44M2026-08-14
Marshall Wace, LLP▼ Sell17,1060.04%$2.17M2026-08-13
D. E. Shaw & Co., Inc.▼ Sell13,4090.03%$1.70M2026-08-14
Q2 2026 flow:2.87M sh bought ($364.51M)302.8K sh sold ($38.25M)net +2.57M sh (+$326.26M)
Congressional Trading Activity
4 disclosed trades · ~$56.5K est. traded value · 2 buys, 2 sells
MemberChamberStateTypeAmountTradedFiled
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-07-222025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-162025-08-13
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-02-252025-03-27
Susan M. CollinsSenateME▲ Buy$15K - $50K2014-11-102014-12-01